Want to see GB:BVXP full AI Analyst Report?
Top Page
Bioventix
(LSE:BVXP)
Select Model
Select Model
Rating:89Outperform
Price Target:
2,378.00 p
▲(35.89% Upside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by top-tier financial performance (high profitability, very low leverage, and strong cash conversion). Technicals add support with a strong uptrend and positive momentum, though momentum indicators are approaching overbought levels. Valuation is also favorable, combining a moderate P/E with a very high dividend yield, while the key watch item remains the recent slowdown in revenue growth.
Positive Factors
Exceptional profitability
Exceptionally high and stable margins indicate strong earnings power in Bioventix’s antibody and diagnostic-reagent model. Sustained profitability provides internal funding for operations and shareholder returns, while creating resilience if revenue growth remains modest over the next several quarters.
Negative Factors
Recent revenue slowdown
The shift from positive revenue growth in 2021–2024 to slight contraction in 2025 and modest growth in 2026 signals weaker top-line momentum. If sustained, slower growth could limit operating leverage, reduce expansion opportunities, and place greater reliance on existing margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Exceptional profitability
Exceptionally high and stable margins indicate strong earnings power in Bioventix’s antibody and diagnostic-reagent model. Sustained profitability provides internal funding for operations and shareholder returns, while creating resilience if revenue growth remains modest over the next several quarters.
Read all positive factors
Bioventix (BVXP) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£103.97M
Dividend Yield7.54%
Average Volume (3M)16.56K
Price to Earnings (P/E)14.0
Beta (1Y)0.57
Revenue Growth-1.10%
EPS Growth0.32%
CountryUK
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.42
Shares Outstanding5,224,860
10 Day Avg. Volume18,759
30 Day Avg. Volume16,556
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)9.01
Price to Sales (P/S)16.16
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioventix Business Overview & Revenue Model
Company Description
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical a...
Bioventix Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
95
Very Positive
Cash Flow
90
Very Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.54M | 12.97M | 13.12M | 13.61M | 12.82M | 11.72M |
| Gross Profit | 11.53M | 11.81M | 11.92M | 12.68M | 11.86M | 10.87M |
| EBITDA | 9.54M | 9.79M | 10.17M | 10.74M | 10.20M | 9.42M |
| Net Income | 7.44M | 7.61M | 7.58M | 8.10M | 8.37M | 7.67M |
Balance Sheet | ||||||
| Total Assets | 13.03M | 12.83M | 12.86M | 13.73M | 13.28M | 13.12M |
| Cash, Cash Equivalents and Short-Term Investments | 5.30M | 5.26M | 5.08M | 6.00M | 5.72M | 6.13M |
| Total Debt | 0.00 | 10.97K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.99M | 1.41M | 1.31M | 1.73M | 1.22M | 1.30M |
| Stockholders Equity | 11.04M | 11.42M | 11.55M | 12.00M | 12.06M | 11.82M |
Cash Flow | ||||||
| Free Cash Flow | 7.92M | 8.02M | 7.01M | 8.33M | 7.89M | 7.55M |
| Operating Cash Flow | 7.96M | 8.09M | 7.03M | 8.34M | 7.90M | 7.56M |
| Investing Cash Flow | -32.75K | -71.60K | 173.16K | 186.06K | 90.51K | -11.76K |
| Financing Cash Flow | -7.76M | -7.84M | -8.12M | -8.25M | -8.30M | -7.92M |
Bioventix Technical Analysis
Positive
1750.00
Price Trends
1707.60
Positive
1648.40
Positive
1638.79
Positive
Market Momentum
90.61
Negative
68.88
Neutral
74.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Positive. The current price of 1750 is below the 20-day moving average (MA) of 1806.50, above the 50-day MA of 1707.60, and above the 200-day MA of 1638.79, indicating a bullish trend. The MACD of 90.61 indicates Negative momentum. The RSI at 68.88 is Neutral, neither overbought nor oversold. The STOCH value of 74.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BVXP.
Bioventix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
89 Outperform | £103.97M | 14.01 | 65.83% | 7.49% | -1.10% | 0.32% | |
52 Neutral | £82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £299.37M | -6.74 | -1293.07% | ― | ― | ― | |
43 Neutral | £6.88M | -5.56 | -97.87% | ― | 7.38% | 44.13% | |
43 Neutral | £10.92M | -10.50 | -46.61% | ― | 28.35% | 57.14% | |
40 Underperform | £15.79M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:BVXP
Bioventix
1,990.00
287.74
16.90%
GB:AVCT
Avacta Group plc
61.50
-7.00
-10.22%
GB:OBD
Oxford BioDynamics
0.12
-0.20
-63.44%
GB:FAB
Fusion Antibodies Plc
5.50
-7.75
-58.49%
GB:4BB
4basebio UK Societas
530.00
-255.00
-32.48%
GB:APTA
Aptamer Group Plc
0.32
-0.53
-62.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.